MASLD (Formerly NAFLD): What Fatty Liver Tells Us About Metabolic Health

A fatty liver often enters the medical record almost by accident. It may appear on an ultrasound or CT scan ordered for something else, or it may be suspected after a change in liver enzymes. Sometimes AST and ALT are completely normal.

That does not make the finding unimportant.

Fat accumulating in the liver can be one of the earlier visible signs that metabolic physiology is changing. Insulin resistance, visceral fat, triglycerides, glucose regulation and cardiovascular risk frequently occupy the same territory.

The terminology has changed as well. What was long called nonalcoholic fatty liver disease (NAFLD) is now generally referred to as metabolic dysfunction-associated steatotic liver disease (MASLD). The newer name is more than semantics. It puts the metabolic component of the condition where it belongs: at the center of the discussion.

NAFLD Became MASLD

For decades, fatty liver occurring outside substantial alcohol use was defined largely by what it was not: nonalcoholic fatty liver disease. The new terminology takes a different approach. MASLD describes hepatic steatosis in the setting of cardiometabolic risk, which better reflects what clinicians commonly see in practice.

You will continue to encounter the term NAFLD in older medical records, published research and internet searches. The underlying clinical issue has not suddenly changed because the name did. For most patients, the newer terminology simply describes the biology more accurately.

What Fat in the Liver Can Tell Us

The liver sits in the middle of glucose and lipid metabolism. When insulin sensitivity deteriorates and more energy is being delivered than the system can comfortably handle, fat can begin accumulating inside liver cells.

That finding may accompany higher fasting insulin, rising triglycerides, visceral fat, impaired glucose control or type 2 diabetes. Genetics, medications, diet, alcohol exposure and other medical conditions can also influence liver fat, which is why fatty liver should not be reduced to a single explanation.

Nor should it be reduced to body weight. Some people with MASLD have obesity. Others do not. A normal BMI does not tell us how much visceral fat someone carries, how insulin-sensitive they are, or what is happening inside the liver.

Normal Liver Enzymes Do Not Rule It Out

AST, ALT and GGT are useful pieces of the liver evaluation, but they are not a direct measurement of liver fat. People with MASLD may have mild elevations, substantial elevations or values that remain within the laboratory reference range.

This distinction matters because normal enzymes can create false reassurance. Conversely, an elevated ALT does not prove that fatty liver is the cause. Alcohol, medications, viral hepatitis, muscle injury and other liver conditions remain part of the differential diagnosis.

Laboratory testing works best when it is interpreted as part of the clinical picture rather than as a verdict from a single number.

The More Important Question Is Fibrosis

Finding fat in the liver is the beginning of the evaluation, not the end of it.

Many people with MASLD never develop advanced liver disease. A smaller group develops metabolic dysfunction-associated steatohepatitis, now called MASH, where steatosis is accompanied by liver-cell injury and inflammation. Fibrosis can develop as the liver responds to ongoing injury, and advanced fibrosis can eventually progress to cirrhosis.

This is why modern liver care has moved toward risk stratification. A commonly used first step is the FIB-4 score, calculated from age, AST, ALT and platelet count. It does not diagnose MASLD, but it can help identify people who are unlikely to have advanced fibrosis and those who may benefit from further testing.

When additional evaluation is warranted, clinicians may use liver-stiffness measurements such as transient elastography or other imaging and specialty testing. The appropriate workup depends on the individual patient and cannot be determined by an online article.

Fatty Liver and Cardiovascular Risk

It is easy to concentrate on the liver and miss the larger concern.

The same metabolic environment associated with MASLD commonly overlaps with hypertension, abnormal lipids, insulin resistance, type 2 diabetes and visceral adiposity. Those factors also influence cardiovascular disease.

For preventive longevity medicine, a finding of fatty liver is therefore an invitation to look outward rather than narrowing the evaluation to AST and ALT. Blood pressure, glucose regulation, fasting insulin, triglycerides, lipoproteins, body composition and overall cardiovascular risk may deserve attention as well.

How HormoneSynergy® Looks at the Pattern

At HormoneSynergy®, we do not treat a fatty liver as an isolated laboratory problem. We are interested in why it is there and what else may be happening metabolically.

A patient with hepatic steatosis may warrant a closer look at fasting glucose and insulin, HOMA-IR, hemoglobin A1c, triglycerides, liver enzymes and body composition. Visceral fat and muscle mass can add useful context because two people at the same body weight can have very different metabolic profiles.

HOMA-IR and fasting insulin can help expose insulin resistance that may not yet be obvious from fasting glucose alone. Our articles on GGT and ALT and AST explain how we interpret those markers within the broader picture.

What Actually Improves Fatty Liver?

The liver is metabolically responsive. In many people, hepatic fat declines when the underlying metabolic environment improves.

That may involve changing food quality and energy intake, increasing physical activity, building or preserving skeletal muscle, reducing excess visceral fat, improving insulin sensitivity and treating associated conditions such as diabetes, hypertension or dyslipidemia when necessary. Alcohol exposure also deserves an honest review because metabolic dysfunction and alcohol do not become harmless when they occur together.

There is no single “fatty liver diet” that fits everyone. At HormoneSynergy®, our nutritional framework generally favors a plant- and protein-forward Mediterranean pattern that can be adjusted for the patient's metabolic needs, body composition and medical history.

Medicine, Not Marketing

Fatty liver has created a large market for detox powders, herbal cleanses and supplements promising to “flush” or “repair” the liver.

That is not how we approach it.

The liver does not need a marketing campaign. It needs the metabolic conditions that allow it to function normally. If insulin resistance, visceral adiposity, excessive alcohol exposure or poor glucose control remain unaddressed, a supplement marketed for liver support does not solve the central problem.

There are now medical therapies for selected patients with more advanced forms of MASH, and treatment options continue to evolve. Those decisions belong in individualized medical care. For the much larger group of people who discover fatty liver earlier, the opportunity is often to identify what is driving it before substantial fibrosis has developed.

Frequently Asked Questions

What is MASLD?

MASLD stands for metabolic dysfunction-associated steatotic liver disease. It is the current term for much of what was previously called nonalcoholic fatty liver disease, or NAFLD, and describes excess liver fat occurring in association with cardiometabolic risk.

Is MASLD the same as NAFLD?

The terms substantially overlap, but the diagnostic framework has changed. NAFLD was defined partly by excluding significant alcohol consumption, while MASLD uses the presence of cardiometabolic risk as part of its definition. Older research and medical records will continue to use NAFLD.

Can you have fatty liver with normal AST and ALT?

Yes. Normal liver enzymes do not rule out hepatic steatosis or significant liver disease. AST and ALT provide useful information but should not be used alone to determine whether fatty liver is present.

Can thin people develop fatty liver?

Yes. MASLD can occur in people without obesity. Visceral fat, insulin resistance, genetics, diet, medications and other metabolic factors can influence liver fat independently of BMI.

Is fatty liver reversible?

Liver fat can decrease substantially when the factors contributing to it improve. The likelihood of complete recovery depends in part on whether inflammation or fibrosis has developed and how advanced the underlying liver disease has become.

What is the difference between MASLD and MASH?

MASLD refers to metabolic dysfunction-associated steatotic liver disease. MASH is a more active form of the disease in which liver fat is accompanied by inflammation and liver-cell injury. Fibrosis may develop as the condition progresses.

How do doctors determine whether fatty liver is serious?

The evaluation may include liver enzymes, platelet count, metabolic testing, imaging and noninvasive fibrosis assessment. FIB-4 is commonly used as an initial fibrosis risk tool, with liver-stiffness testing or specialist evaluation considered when appropriate.

Editorial Transparency

This article is educational and reflects the HormoneSynergy® approach to Preventive Longevity Medicine. It is not intended to diagnose fatty liver disease, determine fibrosis risk, or replace individualized medical care. Liver abnormalities can have many causes and should be evaluated in the context of medical history, medications, alcohol exposure, laboratory findings and appropriate imaging.

Clinical Sources

• American Association for the Study of Liver Diseases — Clinical Assessment and Management of MASLD
• American Association for the Study of Liver Diseases — Noninvasive Liver Disease Assessment
• EASL–EASD–EASO Clinical Practice Guidelines on the Management of MASLD